Surf Bio is a preclinical biopharmaceutical company focused on developing innovative therapeutic solutions using a novel biotechnology platform. This platform centers around a next-generation surfactant designed to enhance drug effectiveness for a variety of medical conditions, including diabetes, oncology, infectious diseases, and gene therapy. By improving therapeutic applications, Surf Bio aims to provide healthcare organizations worldwide with access to new and more effective treatments for patients facing critical health issues.
Sermonix Pharmaceuticals, Inc. is a biotechnology company based in Columbus, Ohio, founded in 2014. The company specializes in the development and commercialization of female-specific oncology products, particularly focusing on late-stage women's health issues. Its primary product, lasofoxifene, is a selective estrogen receptor modulator designed for the treatment of vulvovaginal atrophy and for both the treatment and prevention of post-menopausal osteoporosis. Additionally, Sermonix is involved in developing pharmaceutical drugs aimed at treating ESR1-mutated metastatic breast and gynecological cancers, thereby enhancing the quality of care for women facing these health challenges.
Science 37, Inc. is a technology-driven clinical trial company focused on transforming clinical research through patient-centric models. It has developed NORA (Network Oriented Research Assistant), a cloud-based mobile research platform that facilitates communication between researchers and patients via videos, photographs, and surveys, enabling end-to-end networked clinical trial services. The company also offers the Science 37 Metasite, which enhances access to diverse patient populations for clinical studies, and the Science 37 Platform for decentralized clinical trials. By utilizing its virtual model, Science 37 has demonstrated faster enrollment and higher patient retention, reaching a broader and more representative patient demographic than traditional site-based research. The company serves a wide range of clients, including large pharmaceutical firms, biotechnology companies, universities, and startups. Since its incorporation in 2014, Science 37 has established itself as a leader in virtual clinical trials, leveraging an extensive network of telemedicine investigators and home-health nurses to conduct more decentralized interventional trials than any other organization.
A-Alpha Bio, Inc., founded in 2017 and based in Seattle, Washington, specializes in synthetic biology with a focus on drug development that targets multiple proteins. The company's flagship platform, AlphaSeq, offers innovative cell-based tools for quantitative and high-throughput measurement of protein interactions. This technology accelerates processes such as target discovery, library screening, and preclinical drug characterization, addressing significant bottlenecks in the industry. By providing biologics and molecular glue discovery and optimization services, A-Alpha Bio supports pharmaceutical companies in enhancing binding and specificity for various target proteins. The team comprises experts in synthetic biology, structural biology, and next-generation sequencing, all dedicated to advancing drug discovery methodologies.
Emulate, Inc. specializes in developing organs-on-chips technology that emulates human biology to better understand the effects of diseases, medications, and environmental factors on human health. The company offers organ-chips that replicate the functions of various organs, including the lung, intestine, liver, and skin, and can simulate both normal and disease states. Emulate’s platform aims to provide more accurate predictions of human responses compared to traditional experimental methods, such as cell cultures or animal testing. The company serves a diverse clientele that includes biotechnology and pharmaceutical firms, consumer health and cosmetics companies, government agencies, and academic researchers. Founded in 2013 and based in Boston, Massachusetts, Emulate was previously known as Emulate Living MicroDevices, Inc. It has shifted its focus towards advancing product innovation and safety across multiple sectors, including drug development and personalized medicine.
SomaLogic operates as a protein biomarker discovery and clinical diagnostics company. It offers SOMAmers (Slow-Offrate Modified Aptamers), which are modified nucleic acid-based protein-binding reagents that are specific for their cognate protein; and SOMAscan that provides protein detection and equipment. The company’s SOMAmer/SOMAscan technology enables to discover protein biomarker signatures; drug discovery and development; and clinical diagnostics. Its products have applications in the diagnostics of various diseases in oncology, neurology, cardiovascular and metabolic disease, and other diseases and conditions.
SomaLogic was founded in 1999 and is headquartered in Boulder, Colorado.
Bridge to Life is a U.S.-based company headquartered in Northbrook, Illinois, dedicated to enhancing the field of organ transplantation. The company specializes in the development and licensing of innovative preservation solutions and technologies aimed at improving the quality of organ transplants. By focusing on organ preservation and machine perfusion, Bridge to Life provides essential products that enable organ procurement organizations and transplant centers to store intra-abdominal organs more effectively. The company emphasizes collaboration with surgeons and transplant professionals to advance emerging scientific methods and preservation technologies, positioning itself as a leading supplier in the global market for organ preservation solutions.
Nautilus Biotechnology is a development-stage life sciences company focused on advancing proteomics, the study of proteins and their functions, to enhance therapeutic development and medical diagnostics. The company has created a platform technology that aims to quantify and unravel the complexities of the human proteome. Its flagship product, the Proteomic Analysis System, is a prototype single-molecule instrument designed to facilitate these efforts. The team at Nautilus comprises experts from various disciplines, including protein chemistry, molecular biology, and data science, enabling a multifaceted approach to overcoming challenges in the field. By harnessing this diverse expertise, Nautilus aims to revolutionize drug development and improve healthcare management through personalized and predictive medicine.
Scribe Therapeutics Inc. is a biotechnology company focused on developing innovative therapeutics using CRISPR technology to address genetic disorders. Founded in 2017 and based in Berkeley, California, Scribe specializes in engineering CRISPR enzymes known as X-Editing (XE) molecules, which enhance the efficacy, specificity, and deliverability of genome editing compared to existing methods. The company's proprietary platform enables the creation of custom-engineered enzymes and delivery systems, facilitating precision targeting within the genome. Scribe Therapeutics aims to establish CRISPR-based therapies as a standard in clinical care, expanding access to transformative treatments for a wide range of conditions, including immuno-oncology and degenerative disorders. Through its commitment to overcoming the limitations of current genome editing technologies, Scribe Therapeutics is poised to make substantial contributions to human therapeutics.
AbSci, LLC is a biotechnology company based in Portland, Oregon, specializing in protein production technologies for the biopharmaceutical industry. Founded in 2011, AbSci has developed SoluPro, an innovative expression system utilizing genetically engineered E. coli to facilitate the scalable and cost-effective production of antibodies, antibody fragments, and other soluble recombinant proteins. This technology significantly lowers production costs for both novel and existing biologics, enhancing the efficiency of drug discovery and manufacturing processes. AbSci's therapeutic proteins and antibodies play vital roles in treatments for cancer, hormone-related conditions, autoimmune diseases, and blood disorders. The company's approach integrates biologic drug discovery with cell line development, positioning it as a leader in the advancement of next-generation therapeutics.
Day One Biopharmaceuticals is a clinical-stage biotechnology company focused on developing targeted therapies for genetically defined cancers in patients of all ages, with an initial emphasis on pediatric patients. Founded in 2018 and headquartered in South San Francisco, California, the company aims to address the critical needs of children and adults diagnosed with cancer by creating innovative treatments derived from the biology of childhood cancer. Day One Biopharmaceuticals prioritizes programs that can be swiftly brought to market, thereby providing timely options for families facing cancer diagnoses. Its lead product candidate, DAY101, is an oral, brain-penetrant pan-RAF kinase inhibitor designed to target specific cancer types. The company seeks to license and acquire promising therapeutic products from research institutions and other biotechnology and pharmaceutical companies, striving to enhance the treatment landscape for underserved populations.
IsoPlexis Corp is a life sciences company based in Branford, Connecticut, that specializes in developing a diagnostic platform designed to measure cellular immune responses in patients. Founded in 2013, the company's technology focuses on single-cell detection, allowing for the identification of diverse immune responses at the individual cell level. This platform plays a crucial role in assessing the safety and efficacy of therapeutics, as well as monitoring disease progression. By providing detailed insights into immune responses, IsoPlexis aims to enhance therapeutic development and inform clinical decision-making for healthcare professionals.
IsoPlexis Corp is a life sciences company based in Branford, Connecticut, that specializes in developing a diagnostic platform designed to measure cellular immune responses in patients. Founded in 2013, the company's technology focuses on single-cell detection, allowing for the identification of diverse immune responses at the individual cell level. This platform plays a crucial role in assessing the safety and efficacy of therapeutics, as well as monitoring disease progression. By providing detailed insights into immune responses, IsoPlexis aims to enhance therapeutic development and inform clinical decision-making for healthcare professionals.
Solid Biosciences Inc. is a life science company focused on developing therapies for Duchenne muscular dystrophy (DMD), a severe genetic disorder primarily affecting boys. The company's lead candidate, SGT-001, is a gene transfer therapy currently undergoing a Phase I/II clinical trial aimed at restoring functional dystrophin protein expression in muscle tissues. In addition to SGT-001, Solid Biosciences is advancing Anti-LTBP4, a monoclonal antibody designed to mitigate fibrosis and inflammation by targeting the LTBP4 protein. The company also works on developing biomarkers and wearable assistive devices under the Solid Suit program, which aims to provide therapeutic benefits to patients. Founded in 2013 and headquartered in Cambridge, Massachusetts, Solid Biosciences has established a strategic collaboration with Ultragenyx to further develop and commercialize gene therapies for DMD. The company’s initiatives address a critical need, as there are currently no effective cures or satisfactory treatments for this progressive and life-threatening condition.
Private Equity Round in 2020
Prometheus Biosciences, formerly known as Prometheus Laboratories, is a biotechnology company focused on developing and commercializing innovative pharmaceutical and diagnostic products, primarily for gastrointestinal diseases such as inflammatory bowel disease (IBD). Based in San Diego, California, the company offers a range of diagnostic tests, including Anser IFX, Anser ADA, and IBD sgi Diagnostic, which enable healthcare providers to monitor treatment and optimize patient care. Prometheus also markets therapeutic agents, such as Entocort EC and Imuran, for managing conditions like Crohn's disease and rheumatoid arthritis. Additionally, it provides genetic and serologic testing for celiac disease and lactose intolerance, among other disorders. With a commitment to precision medicine, Prometheus aims to enhance individualized patient care through its advanced diagnostic capabilities and therapeutic solutions. The company was founded in 1995 and operates as a subsidiary of Precision IBD, Inc.
LianBio is a biopharmaceutical company based in Shanghai, China, with an additional office in Princeton, New Jersey. Founded in 2019, the company focuses on the discovery and development of therapeutic drugs aimed at treating oncology and cardiorenal diseases, as well as other medical conditions. LianBio's mission is to enhance access to innovative medicines by partnering with leading organizations in the field to leverage advanced scientific discoveries. The company is dedicated to addressing unmet medical needs in Greater China and other Asian markets by in-licensing assets and building a diverse pipeline of clinically validated product candidates. Its portfolio aims to establish new standards of care across various therapeutic areas, including cardiovascular, oncology, ophthalmology, inflammatory diseases, and respiratory conditions.
Private Equity Round in 2020
Kronos Bio, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing innovative cancer therapeutics. Founded in 2017 and based in San Mateo, California, the company concentrates on targeting dysregulated transcription factors and the associated transcriptional regulatory networks that contribute to cancer progression. Its lead candidate, entospletinib, is a selective inhibitor aimed at spleen tyrosine kinase for treating acute myeloid leukemia. Additionally, Kronos Bio is advancing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9, intended for the treatment of MYC-amplified solid tumors. The company employs advanced techniques, including high-throughput small-molecule microarrays and targeted protein degradation, to discover potent compounds that can effectively modulate challenging cancer targets.
Thrive Earlier Detection Corp. is a healthcare company dedicated to improving cancer detection through innovative technology. It focuses on the development of CancerSEEK, a liquid biopsy test that analyzes genomic mutations in tumor DNA and protein markers in plasma to identify multiple types of cancer at their earliest stages, often before symptoms become apparent. Founded in 2018 and headquartered in Cambridge, Massachusetts, with an additional office in Baltimore, Maryland, Thrive aims to integrate early cancer detection into routine medical care. The company was previously known as Thrive Sciences Inc. and has been a subsidiary of Exact Sciences Corporation since early 2021. Thrive was launched with support from various investors, including Third Rock Ventures and Section 32, reflecting a strong commitment to advancing cancer diagnostics.
Nautilus Biotechnology is a development-stage life sciences company focused on advancing proteomics, the study of proteins and their functions, to enhance therapeutic development and medical diagnostics. The company has created a platform technology that aims to quantify and unravel the complexities of the human proteome. Its flagship product, the Proteomic Analysis System, is a prototype single-molecule instrument designed to facilitate these efforts. The team at Nautilus comprises experts from various disciplines, including protein chemistry, molecular biology, and data science, enabling a multifaceted approach to overcoming challenges in the field. By harnessing this diverse expertise, Nautilus aims to revolutionize drug development and improve healthcare management through personalized and predictive medicine.
Quellis Biosciences, Inc. is a biopharmaceutical company based in Waltham, Massachusetts, dedicated to developing innovative monoclonal antibody therapies for patients with rare diseases. Founded in 2017, the company aims to create next-generation treatments that enhance patient outcomes, particularly for conditions that are underserved by existing therapies. Quellis is supported by a team with extensive expertise in monoclonal antibody discovery and development, as well as experience in biotech investment and company formation. Collaborating with partners from the biotech incubator Viridian LLC and the accelerator Xontogeny LLC, Quellis is focused on optimizing multiple antibody leads to ensure effective therapeutic performance. Their mission is to deliver meaningful medicines that significantly improve the lives of patients facing serious health challenges.
Landos Biopharma, Inc. is a clinical-stage biopharmaceutical company based in Blacksburg, Virginia, specializing in the development of oral therapeutics for autoimmune diseases. Founded in 2017, the company focuses on innovative treatments for conditions such as inflammatory bowel disease (IBD), Crohn's disease, and ulcerative colitis. Its lead product candidate, NX-13, is a novel, gut-selective agonist targeting the NLRX1 pathway. The company also has a diverse pipeline that includes other internally discovered compounds aimed at novel immunometabolic pathways. By developing first-in-class therapeutics, Landos Biopharma seeks to provide effective treatment options for patients suffering from autoimmune conditions.
Kronos Bio, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing innovative cancer therapeutics. Founded in 2017 and based in San Mateo, California, the company concentrates on targeting dysregulated transcription factors and the associated transcriptional regulatory networks that contribute to cancer progression. Its lead candidate, entospletinib, is a selective inhibitor aimed at spleen tyrosine kinase for treating acute myeloid leukemia. Additionally, Kronos Bio is advancing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9, intended for the treatment of MYC-amplified solid tumors. The company employs advanced techniques, including high-throughput small-molecule microarrays and targeted protein degradation, to discover potent compounds that can effectively modulate challenging cancer targets.
Alector, Inc. is a clinical stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases, including Alzheimer's and frontotemporal dementia. The company's lead product, AL001, is a humanized recombinant monoclonal antibody currently in phase II clinical trials for frontotemporal dementia. Additionally, AL101 is in phase I clinical trials for various neurodegenerative diseases, while AL002 and AL003 are undergoing phase 1b trials specifically for Alzheimer's disease. Alector is leveraging advancements in antibody technology, neuroimmunology, and human genetics to create innovative therapeutics. The company maintains a collaboration with Adimab, LLC, which aids in the discovery and optimization of antibody therapeutics. Alector has a pipeline of ten programs in the research and development stage and aims to advance several candidates through pre-clinical development within the next two years. Founded in 2013, Alector is headquartered in South San Francisco, California.
Counsyl is a health technology company specializing in DNA screening for individuals and families. Its services aim to provide critical health information that can influence important decisions regarding behavior, prevention, and preparedness for future health challenges. By leveraging advanced technology, including custom-built robotics and a team of scientists and engineers, Counsyl processes blood and saliva samples with high precision and efficiency. The company has screened over 500,000 patients and collaborated with more than 6,000 healthcare professionals, striving to make DNA screening accessible to a broad audience. Counsyl’s innovative approach has earned recognition, including the Wall Street Journal’s Innovation Award for Medicine, and its Family Prep Screen has significantly aided individuals in understanding crucial genetic information prior to childbearing. The platform has expanded its offerings to include informed pregnancy and cancer screening, emphasizing the integration of sophisticated technology in real-time communication of medical results between patients and healthcare providers.
Landos Biopharma, Inc. is a clinical-stage biopharmaceutical company based in Blacksburg, Virginia, specializing in the development of oral therapeutics for autoimmune diseases. Founded in 2017, the company focuses on innovative treatments for conditions such as inflammatory bowel disease (IBD), Crohn's disease, and ulcerative colitis. Its lead product candidate, NX-13, is a novel, gut-selective agonist targeting the NLRX1 pathway. The company also has a diverse pipeline that includes other internally discovered compounds aimed at novel immunometabolic pathways. By developing first-in-class therapeutics, Landos Biopharma seeks to provide effective treatment options for patients suffering from autoimmune conditions.
Synlogic, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of synthetic biotic medicines aimed at treating metabolic, inflammatory, and cancer-related diseases. The company’s lead therapeutic program, SYNB1618, is an oral therapy currently in Phase I/IIa clinical trials for the treatment of phenylketonuria. Additionally, Synlogic is developing SYNB1891, an intratumoral synthetic biotic medicine that is undergoing Phase I clinical trials for the treatment of solid tumors and lymphoma. The company is also exploring synthetic biotics for more common conditions, including inflammatory bowel disease and secondary hyperoxaluria. Synlogic has established a collaboration with Ginkgo Bioworks to advance its development of these innovative therapies.
Singulex, Inc., a biotechnology company, develops and commercializes direct molecular detection technology solutions. Its solutions enable life science researchers and clinicians to understand and manage disease. The company develops biomarker diagnostic systems that can detect and quantify normal and abnormal protein biomarkers. It is conducting pilot studies to validate Erenna BioAssay System, a digital molecule detection platform, which detects and quantifies molecule biomarkers in clinical samples. The company also offers various custom assay services, such as pilot study services, assay prototyping, assay characterization, and assay validation. The company was formerly known as BioProfile Corporation and changed its name to Singulex, Inc in September 2003. Singulex is based in Hayward, California
Solid Biosciences Inc. is a life science company focused on developing therapies for Duchenne muscular dystrophy (DMD), a severe genetic disorder primarily affecting boys. The company's lead candidate, SGT-001, is a gene transfer therapy currently undergoing a Phase I/II clinical trial aimed at restoring functional dystrophin protein expression in muscle tissues. In addition to SGT-001, Solid Biosciences is advancing Anti-LTBP4, a monoclonal antibody designed to mitigate fibrosis and inflammation by targeting the LTBP4 protein. The company also works on developing biomarkers and wearable assistive devices under the Solid Suit program, which aims to provide therapeutic benefits to patients. Founded in 2013 and headquartered in Cambridge, Massachusetts, Solid Biosciences has established a strategic collaboration with Ultragenyx to further develop and commercialize gene therapies for DMD. The company’s initiatives address a critical need, as there are currently no effective cures or satisfactory treatments for this progressive and life-threatening condition.
VBI Vaccines Inc. is a biopharmaceutical company focused on developing vaccines for infectious diseases and immuno-oncology, with operations in Israel, the United States, and internationally. The company offers Sci-B-Vac, a prophylactic hepatitis B vaccine suitable for various age groups, and is advancing VBI-2601, an immunotherapeutic candidate aimed at achieving a functional cure for chronic hepatitis B. Utilizing its enveloped virus-like particle (eVLP) platform technology, VBI develops vaccines that closely mimic target viruses to elicit strong immune responses. Key candidates in its eVLP program include VBI-1901, a glioblastoma vaccine in Phase I/IIa clinical trials, and VBI-1501, a cytomegalovirus vaccine that has completed Phase I trials. VBI Vaccines also engages in collaboration and licensing agreements with various pharmaceutical and biotechnology entities, including partnerships for the commercialization of its hepatitis B vaccine and the development of a pan-coronavirus vaccine candidate. Headquartered in Cambridge, Massachusetts, the company also has research facilities in Ottawa, Canada.
VBI Vaccines Inc. is a biopharmaceutical company focused on developing vaccines for infectious diseases and immuno-oncology, with operations in Israel, the United States, and internationally. The company offers Sci-B-Vac, a prophylactic hepatitis B vaccine suitable for various age groups, and is advancing VBI-2601, an immunotherapeutic candidate aimed at achieving a functional cure for chronic hepatitis B. Utilizing its enveloped virus-like particle (eVLP) platform technology, VBI develops vaccines that closely mimic target viruses to elicit strong immune responses. Key candidates in its eVLP program include VBI-1901, a glioblastoma vaccine in Phase I/IIa clinical trials, and VBI-1501, a cytomegalovirus vaccine that has completed Phase I trials. VBI Vaccines also engages in collaboration and licensing agreements with various pharmaceutical and biotechnology entities, including partnerships for the commercialization of its hepatitis B vaccine and the development of a pan-coronavirus vaccine candidate. Headquartered in Cambridge, Massachusetts, the company also has research facilities in Ottawa, Canada.
VBI Vaccines Inc. is a biopharmaceutical company focused on developing vaccines for infectious diseases and immuno-oncology, with operations in Israel, the United States, and internationally. The company offers Sci-B-Vac, a prophylactic hepatitis B vaccine suitable for various age groups, and is advancing VBI-2601, an immunotherapeutic candidate aimed at achieving a functional cure for chronic hepatitis B. Utilizing its enveloped virus-like particle (eVLP) platform technology, VBI develops vaccines that closely mimic target viruses to elicit strong immune responses. Key candidates in its eVLP program include VBI-1901, a glioblastoma vaccine in Phase I/IIa clinical trials, and VBI-1501, a cytomegalovirus vaccine that has completed Phase I trials. VBI Vaccines also engages in collaboration and licensing agreements with various pharmaceutical and biotechnology entities, including partnerships for the commercialization of its hepatitis B vaccine and the development of a pan-coronavirus vaccine candidate. Headquartered in Cambridge, Massachusetts, the company also has research facilities in Ottawa, Canada.
Zymeworks Inc. is a clinical-stage biopharmaceutical company based in Vancouver, Canada, that specializes in the discovery, development, and commercialization of biotherapeutics, primarily for cancer treatment. The company’s leading candidates include ZW25, a bispecific antibody currently undergoing Phase I and II clinical trials targeting various cancers, and ZW49, a bispecific antibody-drug conjugate in Phase I trials for advanced HER2-expressing cancers. Zymeworks employs advanced computational biotechnology techniques, utilizing proprietary molecular modeling and high-performance computing to optimize therapeutic antibodies and other protein-based therapeutics. The company has established strategic partnerships and collaborations with several major pharmaceutical firms, including Merck, Eli Lilly, and Bristol-Myers Squibb, among others, to enhance its research and development efforts. Founded in 2003, Zymeworks continues to focus on developing innovative solutions for cancer and other serious diseases.
Solid Biosciences Inc. is a life science company focused on developing therapies for Duchenne muscular dystrophy (DMD), a severe genetic disorder primarily affecting boys. The company's lead candidate, SGT-001, is a gene transfer therapy currently undergoing a Phase I/II clinical trial aimed at restoring functional dystrophin protein expression in muscle tissues. In addition to SGT-001, Solid Biosciences is advancing Anti-LTBP4, a monoclonal antibody designed to mitigate fibrosis and inflammation by targeting the LTBP4 protein. The company also works on developing biomarkers and wearable assistive devices under the Solid Suit program, which aims to provide therapeutic benefits to patients. Founded in 2013 and headquartered in Cambridge, Massachusetts, Solid Biosciences has established a strategic collaboration with Ultragenyx to further develop and commercialize gene therapies for DMD. The company’s initiatives address a critical need, as there are currently no effective cures or satisfactory treatments for this progressive and life-threatening condition.
Outlook Therapeutics is a biopharmaceutical company focused on developing and commercializing monoclonal antibody biosimilar therapeutics. It is advancing its pipeline of 11 biosimilar products, two of which are currently in clinical development. The company employs its BioSymphony biosimilars business model to achieve accelerated development and technical excellence in order to create affordable medicines for patients around the world.
Outlook Therapeutics is a biopharmaceutical company focused on developing and commercializing monoclonal antibody biosimilar therapeutics. It is advancing its pipeline of 11 biosimilar products, two of which are currently in clinical development. The company employs its BioSymphony biosimilars business model to achieve accelerated development and technical excellence in order to create affordable medicines for patients around the world.
GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, specializing in the discovery and development of gene therapy treatments for retinal degenerative diseases and neurodegenerative disorders of the central nervous system. The company utilizes two primary technology platforms: mitochondrial targeting sequences and optogenetics, aiming to preserve or restore vision in patients affected by severe retinal diseases. Its lead product candidates include GS010, an AAV2-based gene therapy currently in Phase III clinical trials for treating Leber hereditary optic neuropathy associated with ND4 gene mutations, and GS030, which is undergoing Phase I/II trials for retinitis pigmentosa and geographic atrophy in dry age-related macular degeneration. Additionally, GenSight is advancing various preclinical programs targeting both ophthalmic and neurodegenerative conditions, reflecting its commitment to innovative solutions for patients with significant vision impairment or blindness. GenSight Biologics was founded in 2012.
Minerva Neurosciences is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat central nervous system (CNS) diseases. Our goal is to transform the lives of patients with improved therapeutic options and a patient-centric focus. Leveraging extensive domain expertise, we have identified and acquired or in-licensed a portfolio of development-stage proprietary compounds with innovative mechanisms of action.
Sevion Therapeutics is a biopharmaceutical company focused on discovering, developing, and acquiring innovative therapies for cancer and immunological diseases. The company advances a pipeline of proprietary and partnered product candidates utilizing its unique antibody technology platforms. This pipeline aims to create biologic therapies targeting previously inaccessible areas, including multispanning membrane proteins and ion channels involved in various diseases. Additionally, Sevion has developed a pioneering protein nanocage system designed for the targeted delivery of nucleic acids and other therapeutic payloads to specific cells. Through its research and development efforts, Sevion is dedicated to addressing critical therapeutic needs in the treatment of cancer and inflammatory diseases.
Spectrum Pharmaceuticals, Inc. is a biopharmaceutical company that specializes in the development and commercialization of oncology and hematology drug products. The company is advancing several key therapies, including ROLONTIS, a long-acting granulocyte colony-stimulating factor aimed at treating chemotherapy-induced neutropenia; Poziotinib, an irreversible tyrosine kinase inhibitor targeting specific mutations in non-small cell lung cancer; and an Anti-CD20-IFNα fusion molecule, currently in Phase I trials for relapsed or refractory non-Hodgkin’s lymphoma. Spectrum has established various partnerships, including co-development and commercialization agreements with Hanmi Pharmaceutical Co. Ltd., as well as licensing agreements with notable institutions such as The University of Texas M.D. Anderson Cancer Center and ImmunGene, Inc. Founded in 1987 and headquartered in Henderson, Nevada, the company was previously known as NeoTherapeutics, Inc. before adopting its current name in December 2002.